Trial Profile
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Colon cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Graft-versus-host disease; Head and neck cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Pharmacyclics Switzerland
- 21 Nov 2023 Planned number of patients changed from 500 to 600.
- 10 Mar 2022 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 12 Jul 2021 This trial has been completed in Germany, according to European Clinical Trials Database record.